HDAC-IN-38

• Description :

  HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) [1].

• UNSPSC :

  12352005

• Target :

  HDAC

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/hdac-in-38.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NO)/C=C/C1=CC=C(C=C1)CNCCCN2C3=C(CCC4=C2C=C(C=C4)Cl)C=CC=C3

• Molecular Formula :

  C27H28ClN3O2

• Molecular Weight :

  461.98

• References & Citations :

  [1]Kaur N, et al. Protective effects of 10,11-dihydro-5H-dibenzo[b, f]azepine hydroxamates on vascular cognitive impairment. Eur J Med Chem. 2020 Feb 1;187:111915.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC3; HDAC5; HDAC6; HDAC8

• CAS Number :

  [2408123-36-2]